View Older Stories View More Recent Stories

May 22, 2024 05:00PM Xenetic Biosciences, Inc. Announces Executive Leadership Transition
May 10, 2024 08:30AM Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
Jan 17, 2024 09:04AM Xenetic Biosciences (XBIO) Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
Jan 17, 2024 09:00AM Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
Nov 10, 2023 08:35AM Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results
Oct 11, 2023 09:05AM Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference
Sep 5, 2023 08:05AM Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Aug 11, 2023 08:05AM Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results
Jul 5, 2023 08:45AM Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series
May 12, 2023 12:31PM Xenetic Biosciences (XBIO) Announces 1-for-10 Reverse Stock Split of Common Stock
May 12, 2023 12:30PM Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock
May 11, 2023 04:30PM Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
May 4, 2023 08:35AM Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development
May 3, 2023 08:35AM Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison
Apr 11, 2023 08:31AM Xenetic Biosciences (XBIO) Enters Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Apr 11, 2023 08:30AM Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Mar 23, 2023 07:35AM Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update
Mar 16, 2023 08:05AM Xenetic Biosciences, Inc. to Present at the Virtual Investor NETs in Cancer Spotlight Event
Jan 17, 2023 08:06AM Xenetic Biosciences (XBIO) Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy
Jan 17, 2023 08:05AM Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy
Jan 11, 2023 01:00PM JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
Jan 5, 2023 08:05AM Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch Event
Nov 16, 2022 08:37AM Xenetic Biosciences (XBIO) Appoints Jonathan Spicer to its Board
Nov 16, 2022 08:35AM Xenetic Biosciences, Inc. Engages Leading NETs Research Expert, Jonathan Spicer, MD, PhD for Advancement of DNase Oncology Platform
Nov 10, 2022 07:05AM Xenetic Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update
Oct 11, 2022 08:06AM Xenetic Biosciences (XBIO) Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics
Oct 11, 2022 08:05AM Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics
Oct 4, 2022 08:00AM Xenetic Biosciences, Inc. Appoints Globally Recognized Oncology Leader, Allan Tsung, MD to its Scientific Advisory Board
Sep 7, 2022 08:05AM Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Aug 12, 2022 08:00AM Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update
Aug 2, 2022 08:05AM Xenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of Cancer
Jul 7, 2022 09:00AM Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study
Jun 2, 2022 02:00PM JTC Team to Host Virtual Investor Innovation in Oncology Featuring Xenetic Biosciences
Jun 2, 2022 08:35AM Xenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology Event
May 18, 2022 08:15AM Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment Conference
May 12, 2022 04:05PM Xenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
Apr 27, 2022 06:33AM Xenetic Biosciences (XBIO) Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Multiple Therapeutic Modalities
Apr 27, 2022 06:30AM Xenetic Biosciences, Inc. Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Multiple Therapeutic Modalities
Mar 23, 2022 08:34AM Xenetic Biosciences (XBIO) Reports FY21 Results, Provides Business Update
Mar 23, 2022 08:30AM Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update
Jan 12, 2022 10:35AM JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th
Nov 12, 2021 08:00AM Xenetic Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update
Sep 9, 2021 08:08AM Xenetic Biosciences (XBIO) Announces Notice of Allowance for XCART Patent
Sep 9, 2021 08:05AM Xenetic Biosciences, Inc. Receives Notice of Allowance for XCART(TM) Patent
Sep 8, 2021 08:00AM Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Aug 13, 2021 08:05AM Xenetic Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update
Jul 28, 2021 02:00PM Xenetic Biosciences, Inc. Announces Closing of $12.5 Million Private Placement Priced at a Premium to Market
Jul 26, 2021 07:02AM Xenetic Biosciences (XBIO) Announces 4.6M Share Private Placement at $2.70/sh
Jul 26, 2021 07:00AM Xenetic Biosciences, Inc. Announces $12.5 Million Private Placement Priced at a Premium to Market
May 12, 2021 07:00AM Xenetic Biosciences, Inc. Reports First Quarter 2021 Financial Results
View More Recent Stories View Older Stories